CAMPTO 100MG/5ML VIAL FOR I.V INFUSION

CAMPTO 100MG/5ML Vial is a crucial medication designed for intravenous infusion, containing Irinotecan Hydrochloride Trihydrate as its active ingredient.

This product is often referenced on leading pharmaceutical platforms like Nahdi Online, and similar specialized medications are also available on e-commerce sites such as and .

It is prescribed by healthcare professionals for specific cancer treatments, demonstrating a commitment to advanced therapeutic options.

Product Details

• Brand: CAMPTO
• Active Ingredient: Irinotecan Hydrochloride Trihydrate
• Strength: 100 mg per 5 ml vial
• Form: Concentrate for solution for intravenous infusion
• Package Size: Typically supplied as 20 vials, each containing 100 mg/5 ml
• Manufacturer: Pfizer

Benefits of Use

CAMPTO (Irinotecan) is an antineoplastic agent primarily used in the treatment of certain types of cancer.

It functions by inhibiting DNA topoisomerase I, an enzyme critical for DNA replication, thereby impeding the growth of cancer cells.

This medication is often a vital component of chemotherapy regimens, particularly for metastatic colorectal cancer and other solid tumors, providing a targeted approach to disease management.

How to Use

CAMPTO 100MG/5ML Vial is intended for professional administration only. It is crucial to follow the prescribing physician's instructions rigorously.

1. The medication should be prepared and administered by qualified healthcare professionals trained in the handling of cytotoxic drugs.
2. It is given as a slow intravenous infusion, typically diluted in appropriate intravenous fluids (e.g., 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP).
3. Dosage and duration of treatment vary depending on the patient's condition, body surface area, and the specific cancer being treated, as well as any concurrent therapies.
4. Patients will be closely monitored during and after infusion for any adverse reactions.

Caution & Warnings

• CAMPTO is a potent chemotherapy agent; it must be administered under the direct supervision of a physician experienced in the use of anticancer agents.
• Patients receiving Irinotecan should be carefully monitored for severe adverse reactions, including myelosuppression (e.g., neutropenia, thrombocytopenia, anemia) and severe diarrhea, which can be life-threatening.
• Antidiarrheal agents should be initiated promptly at the first sign of delayed diarrhea.
• This medication may cause nausea, vomiting, and fatigue. Prophylactic antiemetics may be prescribed.
• Avoid contact with skin and eyes during preparation and administration. Use appropriate protective equipment.
• Not recommended for pregnant or breastfeeding women due to potential harm to the fetus or infant. Effective contraception is advised for patients of reproductive potential during and after treatment.
• Regular blood counts and liver function tests are essential during therapy.
• Inform your doctor of all other medications, supplements, and herbal products you are taking to prevent potential drug interactions.

Ingredients

• Active Ingredient: Irinotecan Hydrochloride Trihydrate
• Excipients: Lactic Acid, Sodium Hydroxide (for pH adjustment), Water for Injection.